Recently, the R21/Matrix-M malaria vaccine which incorporates higher CSP antigen content3, has also shown high protective efficacy of 75% (95% CI 71–79) in four African countries in a phase 3 trial where children aged 5–36 months were sampled from 14 days after third vaccination to 12 months post-vaccination between 2021 and 20224. Here, DNAJC5 is linked to malaria.